Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On-site hepatitis C treatment in homeless people in London with Zepatier
2018-002251-14Phase 4Terminated
- Sponsor
- King's College Hospital
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of grazoprevir and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by King's College Hospital. Started Nov 2018; status: terminated.
02
Drugs
grazoprevirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2018-002251-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002251-14.